The Oncologist, Vol. 7, No. 4, 271-278,
August 2002
© 2002 AlphaMed Press
Staging of Regional Nodes in AJCC Stage I and II Melanoma: 18FDG PET Imaging versus Sentinel Node Detection
Tarik Belhocinea,
Gérald Pierardb,
Michel de Labrassinnec,
Thierry Lahayed,
Pierre Rigoa
a Division of Nuclear Medicine and the Departments of
b Pathology,
c Dermatology, and
d Surgery, University Hospital of Liège, Liège, Belgium
Correspondence:
Tarik Belhocine, M.D., University Hospital of Liège, Division of Nuclear Medicine, Sart Tilman - Bâtiment 35, 4000 Liège, Belgium. Telephone: 324-366-7931; Fax: 324-366-7933; e-mail: tarik.bel{at}swing.be
Primary Purpose. The staging of regional nodes by means of sentinel node detection has been shown to accurately detect subclinical nodal metastases from cutaneous melanoma. On the other hand, the oncological applications of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18FDG PET) are, nowadays, firmly established. However, the sensitivity of such metabolic imaging for staging the regional nodes in primary melanoma remains debatable. We prospectively assessed the actual value of PET for detecting sentinel node metastases in 21 consecutive patients presenting with early-stage melanoma.
Materials and Methods. Twenty-one melanoma patients scheduled for lymphatic mapping and sentinel lymphadenectomy underwent fully corrected whole-body PET using 18FDG. In all cases, the disease was initially classified as either stage I or II, from the latest version of the American Joint Committee on Cancer staging system. The sentinel node detection was systematically performed within the week following the PET scan. Serial sections of the sentinel nodes were analyzed by both conventional pathology and immunohistochemical staining. Metastatic sentinel nodes were also assessed for the size of tumor deposits and the degree of nodal involvement (focal, partial, or massive). The median follow-up time was 12 months.
Results. Six of the 21 patients (28.5%) had an involved sentinel node. PET was positive in only one case with a sentinel node >1 cm. In the five other cases, the sentinel nodes missed by PET were <1 cm with focal and/or partial involvements. One patient, free of regional nodal metastases in both sentinel node detection and PET imaging, had, however, a same-basin recurrence 3 months later. In another case, PET had one false positive result. Overall, the sentinel detection of subclinical nodal metastases had a sensitivity of 86%. PET detected only 14% of sentinel node metastases.
Conclusions. Sentinel node detection remains the procedure of choice for detecting subclinical lymph node involvement from primary cutaneous melanoma. Owing to its limited spatial resolution, PET appears insufficiently sensitive to identify microscopic nodal metastases. As a practical consequence, metabolic imaging is not recommended as a first-line imaging strategy for staging regional lymph nodes in patients with stage I or II melanoma.
Key Words. Cutaneous melanoma • Sentinel node • Lymphatic mapping • 18FDG PET
This article has been cited by other articles:

|
 |

|
 |
 
J W CRAWSHAW, P HADWAY, D HOFFLAND, S BASSINGHAM, C M CORBISHLEY, Y SMITH, J PILCHER, R ALLAN, N A WATKIN (Urol), and S D HEENAN
Sentinel lymph node biopsy using dynamic lymphoscintigraphy combined with ultrasound-guided fine needle aspiration in penile carcinoma
Br. J. Radiol.,
January 1, 2009;
82(973):
41 - 48.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Krug, R. Crott, M. Lonneux, J.-F. Baurain, A.-S. Pirson, and T. Vander Borght
Role of PET in the Initial Staging of Cutaneous Malignant Melanoma: Systematic Review
Radiology,
December 1, 2008;
249(3):
836 - 844.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner
Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma
J. Nucl. Med.,
June 1, 2006;
47(6):
957 - 967.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Reinhardt, A. Y. Joe, U. Jaeger, A. Huber, A. Matthies, J. Bucerius, R. Roedel, H. Strunk, T. Bieber, H.-J. Biersack, et al.
Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients
J. Clin. Oncol.,
March 1, 2006;
24(7):
1178 - 1187.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kizu, T. Takayama, M. Fukuda, M. Egawa, H. Tsushima, M. Yamada, K. Ichiyanagi, K. Yokoyama, M. Onoguchi, and N. Tonami
Fusion of SPECT and Multidetector CT Images for Accurate Localization of Pelvic Sentinel Lymph Nodes in Prostate Cancer Patients
J. Nucl. Med. Technol.,
June 1, 2005;
33(2):
78 - 82.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. F. Kovacs, N. Dobert, J. Gaa, C. Menzel, and K. Bitter
Positron Emission Tomography in Combination With Sentinel Node Biopsy Reduces the Rate of Elective Neck Dissections in the Treatment of Oral and Oropharyngeal Cancer
J. Clin. Oncol.,
October 1, 2004;
22(19):
3973 - 3980.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C A Murray, W L Leong, D R McCready, and D M Ghazarian
Histopathological patterns of melanoma metastases in sentinel lymph nodes
J. Clin. Pathol.,
January 1, 2004;
57(1):
64 - 67.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C.P. Cobben, P. L. Jager, P. H. Elsinga, B. Maas, A. J.H. Suurmeijer, and H. J. Hoekstra
3'-18F-Fluoro-3'-Deoxy-L-Thymidine: A New Tracer for Staging Metastatic Melanoma?
J. Nucl. Med.,
December 1, 2003;
44(12):
1927 - 1932.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Alonso, M. Martinez, L. Delgado, A. De Leon, D. De Boni, G. Lago, M. Garces, F. Fontes, J. Espasandin, and J. Priario
Staging of Regional Lymph Nodes in Melanoma Patients by Means of 99mTc-MIBI Scintigraphy
J. Nucl. Med.,
October 1, 2003;
44(10):
1561 - 1565.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by AlphaMed Press.
|
|